<DOC>
	<DOCNO>NCT01449240</DOCNO>
	<brief_summary>The purpose study collect data CSF biomarkers patient Hunter Syndrome would serve reference data comparison cognitively impaired patient Hunter syndrome , patient lysosomal storage disease , disease CNS involvement .</brief_summary>
	<brief_title>Collection Study Cerebrospinal Fluid Patients With Hunter Syndrome</brief_title>
	<detailed_description>To determine level glycosaminoglycans ( GAGs ) , include dermatan sulfate ( DS ) heparan sulfate ( HS ) , GAG-degradation product , biomarkers central nervous system ( CNS ) lysosomal function cerebrospinal fluid ( CSF ) pediatric adult patient Hunter syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>The patient male document diagnosis Hunter syndrome ( MPSII ) . The adult patient complete cognitive assessment screening/baseline within previous 3 month determine intelligence quotient ( IQ ) â‰¥78 . Note : cognitive evaluation pediatric patient require . The adult patient adult patient 's legally authorize representative ( ) voluntarily sign Institutional Review Board/Independent Ethics Committeeapproved inform consent form relevant aspect study explain discuss . The pediatric patient must schedule undergo nonstudy relate lumbar puncture medical diagnostic procedure require administration general anesthesia . The pediatric patient 's parent ( ) legally authorize representative ( ) must provide write informed consent ( patient assent relevant ) , relevant aspect study explain discuss , allow CSF sample collection study conjunction performance nonstudy related procedure require general anesthesia . The patient history complication previous lumbar puncture ( ) technical challenge conduct lumbar puncture . The patient receive hematopoietic stem cell transplant . The patient take aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ) , overthecounter prescription medication could affect blood clot formation within 7 day prior lumbar puncture , ingested medication within 7 day prior studyrelated procedure change potential blood clot formation would deleterious . The patient currently receive treatment intrathecal idursulfaseIT . The patient currently enrol interventional clinical trial . The patient participate clinical trial investigational drug , include idursulfaseIT , device within 30 day prior study entry .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hunter syndrome</keyword>
	<keyword>Mucopolysaccharidosis II</keyword>
	<keyword>Iduronate 2-Sulfatase Deficiency</keyword>
	<keyword>Lumbar puncture</keyword>
	<keyword>Cerebrospinal fluid ( CSF )</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Adult</keyword>
	<keyword>Biomarkers</keyword>
</DOC>